TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02345902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: haloperidol 1.25 mg P.O q.d

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo 1.25 mg P.O q.d
Study: NCT04650763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated blood cell separator to extract PRP
Description: Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
Study: NCT03455751

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGx-guided post-operative pain management
Description: Post-operative pain management as indicated by pharmacogenomic testing results.
Study: NCT02249429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimiralisib
Description: 60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
Study: NCT02759406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stent
Study: NCT00702871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
Study: NCT02345902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-pharmacologic measures
Description: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-pharmacologic measures
Description: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
Study: NCT04231903

Intervention type: DEVICE
Intervention: Aortic clamp
Description: In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
Study: NCT00702871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucralfate
Description: In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
Study: NCT00513292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT00593528

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)
Description: Vascular Stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)
Description: Vascular Stents

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: Transjugular intrahepatic portosystemic shunt (TIPS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: Transjugular intrahepatic portosystemic shunt (TIPS)
Study: NCT00986661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Description: Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
Study: NCT04641234

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: As prescribed by the treating physician
Study: NCT00663923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photorefractive keratectomy (PRK)
Description: comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photorefractive keratectomy (PRK)
Description: comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
Study: NCT04344236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study: NCT04891848

Intervention type: OTHER
Intervention: inflammation
Description: inflammatory values in complete blood count (CBC)

Intervention type: OTHER
Intervention: inflammation
Description: inflammatory values in complete blood count (CBC)

Intervention type: OTHER
Intervention: inflammation
Description: inflammatory values in complete blood count (CBC)

Intervention type: OTHER
Intervention: inflammation
Description: inflammatory values in complete blood count (CBC)
Study: NCT03670810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.
Study: NCT03670810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT03405142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
Study: NCT02995252

Intervention type: OTHER
Intervention: Blood draws

Intervention type: OTHER
Intervention: Blood draws

Intervention type: DRUG
Intervention: Tenofovir Alafenamide
Description: 25 mg tablet, once a day by mouth.

Intervention type: OTHER
Intervention: Knowledge Index Questionnaire

Intervention type: OTHER
Intervention: Knowledge Index Questionnaire

Intervention type: OTHER
Intervention: Liver transient elastography (FibroScan)
Description: Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: 40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
Study: NCT04117126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompted voiding
Description: Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control.
Study: NCT01299831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 72 hour fast
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control, 12 hour fast
Description: The 12 hour fast will be used as a basic metabolic control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olbetam
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours.
Study: NCT03890731

Intervention type: DRUG
Group type: OTHER
Intervention: BAY73-4506 (Regorafenib, Stivarga)
Description: Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
Study: NCT03441828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of surgical field conditions
Description: evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
Study: NCT01434524

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: LIVACT
Description: LIVACT contains 13.0 g of free amino acids
Study: NCT01820416

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Disabled Laser
Description: Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
Study: NCT04355000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RMGIC restoration
Description: Complete removal of caries and filling will be done with RMGIC material
Study: NCT04364529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The pit crew model
Description: The pit crew model
Study: NCT00097721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
Study: NCT00215046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: drug - dosage and frequency is based on size of patient and response to treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
Study: NCT03352921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pilates exercises
Description: servikal, deep flexor muscles, posture exercsises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises program
Description: stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
Study: NCT01352494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
Study: NCT00499096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic care model for Bipolar Disorder
Description: The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
Study: NCT02737124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be given 24 hours before scheduled surgery.
Study: NCT03441828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality of surgical field conditions
Description: evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Block
Description: maintenance of a deep neuromuscular block by infusion of rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Neuromuscular Block
Description: maintenance of a moderate neuromuscular block.
Study: NCT01388322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
Study: NCT02961361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
Study: NCT02737124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to subjects 24 hours before scheduled surgery.
Study: NCT04344236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Povidone/Iodine oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study: NCT02801565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional controlled ovarian stimulation proctol
Description: Conventional controlled ovarian stimulation proctol without rhGH.
Study: NCT02961361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine mixed with dexmedetomidine
Description: 40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
Study: NCT01629121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated.
Study: NCT05149716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
Study: NCT02456272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External hearing aid
Description: The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Otosclerosis surgery
Description: Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
Study: NCT01727804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser in caries prevention
Study: NCT04647773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 60mg BID
Description: HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 80mg BID
Description: HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg BID
Description: Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
Study: NCT05149716

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
Study: NCT03950947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug
Description: See above

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Controll
Description: Angiography of the RIMA without occlusion
Study: NCT01714726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI2070
Description: 1 iv infusion on Week 0 and Week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI2070
Description: 1 iv infusion on Week 0 and Week 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 iv infusion on Week 0 and Week 4
Study: NCT01768169

Intervention type: DIETARY_SUPPLEMENT
Intervention: fish oil capsule
Description: 500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
Study: NCT02022566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A supported self management of osteoarthritis program
Description: Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.